Steve E. Krognes, Director at Denali Therapeutics Inc. (DNLI), sold 4,506 shares at $33.22 ($150K) on 2022-08-19, disclosed to the SEC on 2022-08-23.
Seasonal sale ($150k) by Director — this insider has traded DNLI in August in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $33.22 | 2,253 | $75K | 50.0% |
| 2 | $33.22 | 2,253 | $75K | 50.0% |
| Total | $33.22 avg | 4,506 | $150K | 100% |
| Filing → |
| DNLI | SELL | 2025-01-08 | $139K | — | Filing → |
| DNLI | SELL | 2025-01-03 | $608K | — | Filing → |
| DNLI | SELL | 2024-10-02 | $871K | — | Filing → |